Viewing Study NCT00591734

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:25 AM
Ignite Modification Date: 2026-02-07 @ 12:30 PM
Study NCT ID: NCT00591734
Status: COMPLETED
Last Update Posted: 2021-11-24
First Post: 2007-12-26
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: RAD001 Plus Bevacizumab in Metastatic Melanoma
Sponsor: SCRI Development Innovations, LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic Melanoma View
None Everolimus View
None RAD001 View
None Bevacizumab View